Vertex Pharmaceuticals Incorporated

🇺🇸NASDAQ Global Select
Back to all articles
Vertex Pharmaceuticals Incorporated stock analysis VRTX overview
Slightly Bullish +25

Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect - Yahoo Finance

📅 Vertex Pharmaceuticals is scheduled to report first-quarter 2026 earnings after market close on May 4.

💰 Analysts expect revenue of $2.98 billion and earnings per share of $4.20 for the upcoming quarter.

💊 Sales will likely be driven by strong demand for its CF blockbuster medicine, Trikafta/Kaftrio, with estimates at $2.40 billion.

📉 Higher sales of Trikafta/Kaftrio are expected to cause some sales erosion in Vertex's other cystic fibrosis drugs.

💧 Investors will focus on the performance of the fifth CF medicine, Alyftrek, which showed sequential sales growth last quarter.

💉 The novel non-opioid pain medicine Journavx, approved in January 2025, is expected to drive higher sales with rising prescription volumes.

🧬 Vertex leads global development and commercialization of CRISPR Therapeutics' gene therapy Casgevy for blood disorders.

📈 Casgevy sales increased significantly last quarter due to robust patient growth and improving reimbursement access.

🏥 Investors will seek updates on positive launch metrics for Casgevy, including growing cell collections and infusions.

⚠️ Vertex shares have fallen 6.1% year to date, outperforming the industry's decline of just 1.2%.

🎢 The company has a mixed earnings history with two beats and two misses over the trailing four quarters.

📉 Vertex recently posted a negative earnings surprise of 0.79% in its last reported quarter.

📊 Zacks Investment Research estimates an average Earnings ESP of -0.54% with a consensus estimate lower than expected revenue.

🏅 Vertex currently carries a Zacks Rank #3, suggesting the company is less likely to beat earnings compared to higher-ranked stocks.

🧪 Updates on Vertex's pipeline candidates for pain, kidney diseases, and type I diabetes are also expected during the earnings call.

Bullish Signals
  • Vertex's blockbuster CF medicine Trikafta/Kaftrio is expected to drive revenues with the Zacks Consensus Estimate pegged at $2.40 billion.
  • Alyftrek (vanza triple) sales increased sequentially in the last reported quarter and are projected to continue growing as its U.S. launch progresses well across all patient groups.
  • The ex-U.S. launch of Alyftrek is showing a strong start in multiple European countries where patients have reimbursed access.
  • Casgevy sales increased significantly on a sequential basis due to robust patient growth and rapid progress in the drug's access and reimbursement.
  • Vertex expects significant growth in Casgevy's sales in 2026 as launch metrics look positive with growing cell collections and product infusions.
  • Journavx (suzetrigine) was approved by the FDA in January 2025 and saw improved sequential sales driven by strong prescription growth.
  • The drug's launch metrics and early reimbursement progress for Journavx look favorable with higher sales expected in the first quarter as prescription volumes are rising.
Risk Factors
  • Shares of Vertex have plunged 6.1% year-to-date, significantly outperforming the industry's decline of only 1.2%, indicating weaker investor sentiment.
  • Vertex has a mixed track record with earnings surprises over the trailing four quarters, missing estimates on two occasions and posting a negative earnings surprise of -0.79% in the last reported quarter.
  • The Most Accurate Estimate for earnings currently stands at $4.18 per share, which is lower than the Zacks Consensus Estimate of $4.20 per share, suggesting potential downside pressure on the upcoming report.
  • Vertex currently carries a Zacks Rank #3 (Hold), reflecting mixed analyst confidence compared to higher-ranked peers like Agenus and Inovio.
  • Earnings ESP stands at -0.54%, indicating that the company is expected to miss consensus estimates based on recent data and model analysis.
Full Analysis
Vertex Pharmaceuticals is scheduled to report its first-quarter 2026 earnings on May 4, following the market close. Analysts at Zacks have pegged the consensus revenue estimate at $2.98 billion and earnings per share at $4.20. Revenue growth is expected to be primarily driven by strong demand for its cystic fibrosis blockbuster drug Trikafta/Kaftrio, with sales estimates standing at $2.40 billion for the quarter. However, this success has come with some headwinds as higher sales of Trikafta/Kaftrio have contributed to sales erosion in Vertex's other CF medicines, including Symdeko, Orkambi, and Kalydeco. Beyond its established franchise, investors will closely examine performance data for Alyftrek (vanza triple), the company's fifth CF medicine. Following a sequential increase in the prior quarter, Alyftrek has shown strong launch progress both domestically and internationally, with positive reimbursement access in multiple European markets. Additionally, growth from Casgevy, the CRISPR Therapeutics gene therapy approved in late 2023/early 2024 for sickle cell disease and beta-thalassemia, will be a key highlight. Casgevy sales increased significantly in the previous quarter due to robust patient growth, with Vertex anticipating significant revenue expansion in 2026 as launch metrics remain positive. The pipeline also includes Journavx (suzetrigine), a novel non-opioid pain medicine approved by the FDA in January 2025, which posted sequential sales improvements driven by prescription volume increases. The upcoming earnings call is expected to provide updates on Vertex's broader pipeline, including mid- to late-stage candidates for acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, and cell therapy for type I diabetes. Despite strong product performance, the stock has underperformed the industry recently, with shares falling 6.1% year to date compared to a 1.2% decline in the broader healthcare sector. Vertex has posted mixed earnings results over the trailing four quarters, missing estimates by 0.79% in its most recent report and carrying a negative Earnings ESP of -0.54%.